Abstract
Background
This study retrospectively analyzed the laboratory data and chest images of patients
with amyopathic dermatomyositis associated with interstitial lung disease (ADM-ILD)
and patients with other connective tissue disease-related ILDs (CTD-ILDs) to find
a characteristic index for the early recognition of ADM-ILD and help clinicians consider
the possibility of ADM-ILD as soon as possible.
Methods
In our cohort study, the records of 128 Chinese patients with CTD-ILD, including 33
ADM-ILD patients, 37 rheumatoid arthritis (RA)-ILD patients, 33 primary Sjogren's
syndrome (pSS)-ILD patients, 14 systemic sclerosis (SSc)-ILD patients and 11 systemic
lupus erythematosus (SLE)-ILD patients. The patients’ clinical features, laboratory
parameters, and chest HRCT findings were analyzed.
Results
ADM-ILD patients generally had significantly higher LDH (333.52±160.21 U/L), AST (66.21±83.66
U/L), and CK-MB (18.23±8.28 U/L) levels than other CTD-ILD patients. A total of 90.91%
(30/33) of ADM-ILD patients had elevated LDH. Patients with ADM-ILD were more prone
to organizing pneumonia radiologic patterns on chest HRCT scans than patients with
other CTD-ILDs (=37.39, p < 0.001) and were found in 18 of 33 ADM-ILD patients. Anti-MDA5 (45.45%) was the
most commonly detected autoantibody in ADM-ILD patients, followed by anti-PL-7 (21.21%),
anti-Jo-1 (12.12%), and anti-PL-12 (9.09%), and levels of ALT (96.93±119.79 vs. 17.50±6.218
U/L), AST (113.00±106.13 vs. 23.56±6.91 U/L), LDH (415.00±198.51 vs. 261.94±67.75
U/L) and CK-MB (22.57±5.91 vs. 14.61±8.36 U/L) were significantly higher in anti-MDA5-positive
patients, but these patients had significantly lower WBC counts (4.82±2.61 vs. 7.14±3.00 × 109/L), lymphocyte counts (0.72±0.20 vs. 1.23±0.53 × 109/L), and ALB levels (31.90±4.76 vs. 35.49±4.71 g/L).
Conclusions
ADM-ILD patients have higher serum LDH, AST and CK-MB levels, especially serum LDH
levels, and are more prone to organizing pneumonia radiologic patterns on chest HRCT
scans than other CTD-ILD patients. A high level of serum LDH with ILD may be a useful
characteristic index for recognizing ADM-ILD.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of the Medical SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Inflammatory muscle diseases.N Engl J Med. 2015; 372: 1734-1747
- Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients.Arthritis Rheum. 2011; 63: 3439-3447
- Overlap myositis, a distinct entity beyond primary inflammatory myositis: a retrospective analysis of a large cohort from the REMICAM registry.Int J Rheum Dis. 2019; 22: 1393-1401
- Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease.Clin Rheumatol. 2019; 38: 803-815
- Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?.J Am Acad Dermatol. 2002; 46: 626-636
- Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases.Rheumatology. 2021; 60 (Oxford): 1195-1204
- Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.Arch Dermatol. 2010; 146: 729-738
- Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.Respir Med. 2018; 140: 1-5
- Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients.Rheumatol Int. 2013; 33: 1295-1302
- Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US Patients with amyopathic and myopathic dermatomyositis.Arthritis Care Res. 2016; 68 (Hoboken): 689-694
- Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.Clin Rheumatol. 2007; 26: 1647-1654
- Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis.Chest. 2009; 136: 1341-1347
- Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.Arthritis Care Res. 2013; 65 (Hoboken): 1316-1324
- Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias.BMC Pulm Med. 2017; 17: 134
- Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.Rheumatol Int. 2016; 36: 125-131
- Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis.J Rheumatol. 2008; 35: 254-259
- An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med. 2013; 188: 733-748
- Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease.N Engl J Med. 2019; 381: 291-293
- Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.Rheumatology. 2018; 57 (Oxford): 2114-2119
- Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment.JAMA Dermatol. 2016; 152: 944-945
- Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis.Chin Med J. 2020; (Engl): 644-649
- Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases.Respir Med. 2007; 101: 1406-1411
- Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.Semin Arthritis Rheum. 2020; 50: 776-790
- Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model.Chest. 2020; 158: 1535-1545
- HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients.Clin Rheumatol. 2015; 34: 707-714
- Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.Eur J Dermatol. 2019; 29: 511-517
- Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis.Mod Rheumatol. 2011; 21: 178-183
- Clinical features of thirty-two patients with anti-melanoma differentiation-associated gene 5 antibodies.Clin Exp Rheumatol. 2019; 37: 803-807
- Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.Clin Rheumatol. 2016; 35: 113-116
- HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.Respir Med. 2011; 105: 1380-1387
- High-resolution CT findings of myositis-related interstitial lung disease.Medicina. 2021; 57 (Kaunas)
- Myositis specific antibodies are associated with isolated anti-Ro-52 associated interstitial lung disease.Rheumatology. 2021; (Oxford)
- Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis: case report and literature review.J Gen Intern Med. 2021; 36: 3865-3868
- Clinically amyopathic dermatomyositis with anti-transcriptional intermediary factor 1-gamma autoantibody positivity.Rheumatology. 2020; 59 (Oxford): e68-e69
- Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature.Medicine. 2012; 91 (Baltimore): 206-211
- Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection.BMC Rheumatol. 2021; 5: 59
- Presence of Anti-MDA5 antibody and its value for the clinical assessment in patients With COVID-19: a retrospective cohort study.Front Immunol. 2021; 12791348
- Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.Mod Rheumatol Case Rep. 2021; 5: 101-107
- The seasonality of Dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger.Autoimmun Rev. 2021; 20102788
- Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry.Rheumatol Int. 2021; 41: 1021-1036
Article info
Publication history
Published online: December 12, 2022
Accepted:
December 9,
2022
Received:
April 21,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
